API reference
Triclabendazole
- CAS number
- 68786-66-3
- Molecular formula
- C14H9Cl3N2OS
- Molecular weight
- 359.7 g/mol
About this molecule
Triclabendazole, manufactured by Novartis pharmaceuticals, is an antihelminthic drug that was approved by the FDA in February 2019 for the treatment of fascioliasis in humans. Fascioliasis is a parasitic infection often caused by the helminth, Fasciola hepatica, which is also known as “the common liver fluke” or “the sheep liver fluke” or by Fasciola gigantica, another helminth. These parasites can infect humans following ingestion of larvae in contaminated water or food. Triclabendazole was previously used in the treatment of fascioliasis in livestock, but is now approved for human use. This drug is currently the only FDA-approved drug for individuals with fascioliasis, which affects 2.4 million people worldwide.
Source: DrugBank, via PubChem.
Identifiers
- IUPAC name
- 6-chloro-5-(2,3-dichlorophenoxy)-2-methylsulfanyl-1H-benzimidazole
- InChIKey
- NQPDXQQQCQDHHW-UHFFFAOYSA-N
- SMILES
- CSC1=NC2=CC(=C(C=C2N1)Cl)OC3=C(C(=CC=C3)Cl)Cl
- PubChem CID
- 50248
Also known as
Triclabendazole · Fasinex · Triclabendazol · Egaten · Triclabendazolum · EGA230B · Egaten tm · Triclabendazole Micronized
Chemical data on this page is drawn from PubChem (National Library of Medicine) and is provided for identification only. Hanpars does not hold stock of every substance listed; availability, grade, documentation and regulatory status are confirmed per enquiry.
Tell us the grade, the quantity and the market.
Send the molecule or ingredient, the specification and the destination. We reply from Tehran with the questions, the documents and the next step.